Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Biochem Mol Toxicol ; 38(3): e23669, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38459698

ABSTRACT

Paclitaxel (PTX) is a chemotherapeutic agent that is widely used for the treatment of several types of tumors. However, PTX-induced peripheral neuropathy (PIPN) is an adverse effect generally induced by long-term PTX use that significantly impairs the quality of life. Necroptosis has been implicated in various neurodegenerative disorders. Necroptosis of dorsal root ganglion neurons triggers the pathogenesis of PIPN. Therefore, the present study aims to investigate the role of spinal neuronal necroptosis in PIPN. It also explores the potential role of microglial polarization in necroptosis. We established rat models of PIPN via quartic PTX administration on alternate days (accumulated dose: 8 mg/kg). PTX induced obvious neuronal necroptosis and upregulated the expression of receptor-interacting protein kinase (RIP3) and mixed lineage kinase domain-like protein (MLKL) in the spinal dorsal horn. These effects were inhibited with a necroptosis pathway inhibitor, necrostatin-1 (Nec-1). The effect of microglial polarization on the regulation of spinal necroptosis was elucidated by administering minocycline to inhibit PTX-induced M1 polarization of spinal microglia caused by PTX. We observed a significant inhibitory effect of minocycline on PTX-induced necroptosis in spinal cord cells, based on the downregulation of RIP3 and MLKL expression, and suppression of tumor necrosis factor-α and IL-ß synthesis. Additionally, minocycline improved hyperalgesia symptoms in PIPN rats. Overall, this study suggests that PTX-induced polarization of spinal microglia leads to RIP3/MLKL-regulated necroptosis, resulting in PIPN. These findings suggest a potential target for the prevention and treatment of neuropathic pain.


Subject(s)
Neuralgia , Paclitaxel , Rats , Animals , Paclitaxel/adverse effects , Microglia/pathology , Necroptosis , Minocycline/adverse effects , Quality of Life , Neuralgia/chemically induced
2.
J Clin Immunol ; 29(3): 387-95, 2009 May.
Article in English | MEDLINE | ID: mdl-19172384

ABSTRACT

BACKGROUND: The nuclear factor kappa B (NF-kappaB) pathway is a critical mediator of regulated on activation, normal T cell expressed and secreted (RANTES) gene regulation and therefore represents a potential target for therapy of endometriosis-associated symptoms. OBJECTIVE: The objective of this study was to investigate the effect of NF-kappaB decoy oligonucleotides (ODNs) on NF-kappaB activation, RANTES expression, and monocyte chemotactic activity in ectopic endometrial stromal cells in vitro. METHODS: A specific sandwich enzyme-linked immunosorbent assay (ELISA) was used to quantify RANTES expression in ectopic and normal endometrial stromal cells stimulated by interleukin (IL)-1beta. Four hours after transfection of NF-kappaB decoy ODNs, 10 ng/ml IL-1beta was added to induce the ectopic endometrial stromal cells to secrete RANTES. The NF-kappaB activation, RANTES expression, and monocyte chemotactic activity in ectopic endometrial stromal cells were respectively evaluated by electrophoretic mobility shift assay, ELISA, and Boyden chambers. RESULTS: IL-1beta induced significantly higher levels (P < 0.05) of RANTES expression in a time-dependent manner in ectopic endometrial stromal cells compared with IL-1beta-untreated ectopic and normal endometrial stromal cells. The RANTES accounts for the majority (68%) of the monocyte chemotactic activity in conditioned media of ectopic endometrial stromal cells. In vitro transfection of NF-kappaB decoy ODNs dramatically decreased (P < 0.05) the NF-kappaB activation, RANTES expression, and monocyte chemotactic activity in IL-1beta-induced ectopic endometrial stromal cells. CONCLUSIONS: NF-kappaB decoy ODNs may exert anti-inflammatory effects in ectopic endometrial stromal cells via the suppression of NF-kappaB activation, RANTES expression, and monocyte chemotactic activity.


Subject(s)
Chemokine CCL5/metabolism , Endometriosis/genetics , Endometrium/metabolism , Monocytes/metabolism , Pelvic Inflammatory Disease/genetics , Stromal Cells/metabolism , Cell Migration Inhibition , Chemokine CCL5/genetics , Chemokine CCL5/immunology , Choristoma/metabolism , Choristoma/pathology , Endometriosis/pathology , Endometriosis/therapy , Endometrium/pathology , Female , Humans , Monocytes/immunology , NF-kappa B/antagonists & inhibitors , Oligodeoxyribonucleotides/genetics , Oligonucleotides , Pelvic Inflammatory Disease/pathology , Pelvic Inflammatory Disease/therapy , Pregnancy , Stromal Cells/immunology , Stromal Cells/pathology , Targeted Gene Repair , Transfection
3.
Mol Immunol ; 46(11-12): 2413-8, 2009 Jul.
Article in English | MEDLINE | ID: mdl-19447495

ABSTRACT

OBJECTIVE: The aim of the present study was to assess the anti-inflammatory effects of selective ER beta (ER beta) agonist on lipopolysaccharide (LPS)-induced inducible nitric oxide synthase (iNOS) production in peritoneal macrophages (PMs) of endometriosis (EMS). METHODS: ER alpha (ER alpha) and ER beta expressions in PMs were analyzed by RT-PCR and immunoblot. The PMs of endometriosis were exposed to increasing concentrations of ER beta agonist ERB-041 over a period from 0.5 to 8h before stimulation with LPS and the levels of iNOS protein were evaluated by immunoblot. Subsequently, the PMs were pretreated with vehicle, ERB-041 or ER alpha agonist PPT before exposing to LPS. iNOS expression, p65 protein and active extracellular signal-regulated kinases (ERKs) level accumulated in the nuclear were detected by immunoblot. For experiment investigating the role of ERKs in LPS-induced iNOS expression, the PMs were pretreated with U0126, a specific ERK inhibitor, for 60 min before LPS treatment and iNOS expression was detected by immunoblot. RESULTS: The PMs of EMS expressed ER beta to a greater extent compared with normal women. Pretreatment the PMs with ERB-041 resulted in a significant inhibition of LPS-induced iNOS expression and NF-kappaB activation by preventing its nuclear translocation. The ERKs pathway was involved in the LPS-induced iNOS production and was not repressed by the activation of ERs. CONCLUSION: The inhibitory effect of ER beta agonist on LPS-induced iNOS production in PMs of EMS is likely mediated via repressing of nuclear factor-kappa B (NF-kappaB) but not ERKs signaling pathways.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Endometriosis/enzymology , Estrogen Receptor beta/agonists , Macrophages, Peritoneal/drug effects , NF-kappa B/antagonists & inhibitors , Nitric Oxide Synthase Type II/metabolism , Oxazoles/pharmacology , Cells, Cultured , Endometriosis/immunology , Endometriosis/pathology , Estrogen Receptor beta/metabolism , Extracellular Signal-Regulated MAP Kinases/physiology , Female , Humans , Lipopolysaccharides/pharmacology , Macrophage Activation/drug effects , Macrophages, Peritoneal/enzymology , NF-kappa B/metabolism , Nitric Oxide Synthase Type II/antagonists & inhibitors , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL